Study Finds Donepezil Does Not Increase Risk of Death or Heart Abnormalities

A recent study by McMaster University reveals that the dementia medication donepezil does not increase the risk of death or specific heart rhythm abnormalities, contrary to previous warnings. The findings, published in the Journal of the American Geriatrics Society, are based on a systematic review and meta-analysis of 60 trials involving over 12,000 individuals. This research provides valuable insights into the safety of donepezil, offering reassurance to patients and healthcare providers.